Active Akt1 Prevents Cell Death and Reduces Chemotherapy Sensitivity
Author Information
Author(s): Schmidt M, Hövelmann S, Beckers T L
Primary Institution: ASTA Medica Oncology
Hypothesis
Does a novel form of constitutively active Akt1 affect apoptosis and chemosensitivity in cancer cells?
Conclusion
The study found that constitutively active Akt1 can prevent anoikis and reduce sensitivity to certain chemotherapeutic agents.
Supporting Evidence
- MCF10A cells expressing active Akt1 did not undergo anoikis under low serum conditions.
- A549 cells with active Akt1 showed decreased sensitivity to Mitoxantrone and cisplatin.
- Control cells were more sensitive to chemotherapy compared to those expressing active Akt1.
Takeaway
Scientists created a special version of a protein called Akt1 that helps cancer cells survive when they shouldn't, making it harder for chemotherapy to work.
Methodology
The study involved creating stable cell lines of mammary epithelial and lung cancer cells expressing a modified Akt1 and testing their response to chemotherapy and anoikis.
Limitations
The study primarily focused on specific cancer cell lines and may not generalize to all cancer types.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website